MRI evaluation of residual tumor size after neoadjuvant endocrine therapy vs. neoadjuvant chemotherapy

作者：Takeda Kazuna; Kanao Shotaro^*; Okada Tomohisa; Ueno Takayuki; Toi Masakazu; Ishiguro Hiroshi; Mikami Yoshiki; Tanaka Shiro; Togashi Kaori

来源：European Journal of Radiology, 2012, 81(9): 2148-2153.

DOI：10.1016/j.ejrad.2011.05.013

• MRI
• Breast cancer
• Neoadjuvant endocrine therapy
• Neoadjuvant chemotherapy
• Residual tumor size

Aim: To investigate if there is any difference in evaluation of residual tumor size after neoadjuvant chemotherapy (NAC) and neoadjuvant endocrine therapy (NAE).
Methods: Seventy-eight tumors in 57 patients were prospectively enrolled. Residual tumor sizes in contrast-enhanced MRI after NAC and NAE were compared with those measured on surgical specimen by using linear regression analyses. The line slope values >1 indicates overestimation by MRI. Differences in types of shrinkage patterns: concentric shrinkage (CS) and dendritic shrinkage (DS) were also investigated.
Results: Fifty lesions were treated with NAC and 28 lesions were treated with NAE. Shrinkage patterns were CS in 33 lesions and in 45 lesions. The slopes values were 0.75 (R = 0.92) and 0.70 (R = 0.90) for NAC and NAE, respectively, and no significant difference was observed (p = 0.46). However, they were 1.02 (R = 0.92) and 0.68 (R = 0.92), respectively for CS and DS with significant difference (p < 0.01). The difference between CS and DS was found only in a subgroup with size by MRI >20mm.
Conclusion: Contrast enhanced MRI enabled fairly accurate measurement in NAE as well as in NAC.

• 出版日期2012-9